Abstract
Cardiac-directed expression of AC6 has pronounced favorable effects on cardiac function possibly not linked with cAMP production. To determine rigorously whether cAMP generation is required for the beneficial effects of increased AC6 expression, we generated a catalytically inactive AC6 mutant (AC6mut) that has markedly diminished cAMP generating capacity by replacing aspartic acid with alanine at position 426 in the C1 domain (catalytic region) of AC6. Gene transfer of AC6 or AC6mut (adenovirus-mediated) in adult rat cardiac myocytes resulted in similar expression levels and intracellular distribution, but AC6mut expression was associated with marked reduction in cAMP production. Despite marked reduction in cAMP generation, AC6mut influenced intracellular signaling events similarly to that observed after expression of catalytically intact AC6. For example, both AC6 and AC6mut reduced phenylephrine-induced cardiac myocyte hypertrophy and apoptosis (p < 0.001), expression of cardiac ankyrin repeat protein (p < 0.01), and phospholamban (p < 0.05). AC6mut expression, similar to its catalytically intact cohort, was associated with increased Ca2+ transients in cardiac myocytes after isoproterenol stimulation. Many of the biological effects of AC6 expression are replicated by a catalytically inactive AC6 mutant, indicating that the mechanisms for these effects do not require increased cAMP generation.
Introduction
Adenylyl cyclase (AC) is the effector molecule for β-adrenergic receptor and other G-protein-coupled receptors in cardiac myocytes and other cells. AC regulates the conversion of ATP to cAMP and initiates a variety of intracellular signaling events that influence heart function (Post et al., 1995; Hanoune et al., 1997; Tesmer and Sprang, 1998; Hurley, 1999). Nine isoforms of mammalian AC have been identified so far, all possessing a short intracellular amino terminus and two large cytoplasmic domains (C1 and C2) separated by two transmembrane domains (M1 and M2), each containing six transmembrane spans (Sunahara et al., 1996; Hanoune et al., 1997; Smit and Iyengar, 1998; Tesmer and Sprang, 1998; Hurley, 1999). The C1 and C2 domains form the catalytic core of AC and have activity with or without the two transmembrane domains (Tang and Gilman, 1995; Whisnant et al., 1996; Yan et al., 1996). The catalytic activity of AC is regulated by many factors: GTP-binding proteins, ATP, Mg2+, glycosylation, and phosphorylation (Iwami et al., 1995; Dessauer and Gilman, 1996; Dessauer et al., 1997, 2002; Tesmer et al., 1997; Wu et al., 2001; Lin et al., 2002; Chen-Goodspeed et al., 2005). However, intracellular AC seems to interact with intracellular proteins and influence signaling independently of its catalytic activity. For example, interaction of AC type 6 (AC6) with a PH-domain leucine-rich phosphatase protein 2 (PHLPP2) inhibits PHLPP2 activity, which leads to increased Akt phosphorylation and activity (Brognard et al., 2007; Gao et al., 2009).
β-adrenergic receptor activation or pharmacological reagents that increase cAMP have deleterious effects on the heart (Gaudin et al., 1995; Communal et al., 1998; Engelhardt et al., 1999, 2001; Bisognano et al., 2000; Singh et al., 2001). However, increased expression of AC6, which increases agonist-stimulated cAMP, has beneficial effects (Gao et al., 1999, 2002; Roth et al., 1999, 2002; Lai et al., 2000, 2004, and 2008; Takahashi et al., 2006), suggesting that AC6 expression has biological effects that may be unrelated to cAMP generation. Using pharmacological inhibitors, our previous data support this notion (Gao et al., 2004 and 2008). Because of the inherent limitations of studies using pharmacological inhibition, we generated a catalytically inactive AC6 mutant (AC6mut) molecule by substitution of alanine for aspartic acid at position 426 in the C1 domain of the catalytic core. Based on the crystal structure of the C1C2 catalytic core resolved by Tesmer et al. (1997), this amino acid is required for magnesium binding but is not critical for the overall structure of the catalytic core. This catalytically inactive mutant of AC6 enabled us to determine whether the beneficial effects of AC6 on intracellular signaling, calcium handling, and cardiac myocyte hypertrophy and apoptosis are cAMP-independent.
Materials and Methods
Adult Rat Cardiac Myocyte Culture and Gene Transfer.
Adult rat cardiac myocytes were isolated from 10-week-old Sprague-Dawley rats as described previously (Patel et al., 2006). Isolated cardiac myocytes were suspended in M199 medium (Invitrogen, Carlsbad, CA) supplemented with 1% bovine serum albumin (HyClone, Logan, UT), 100 IU/ml penicillin, and 100 mg/ml streptomycin (Invitrogen, Carlsbad, CA), and were plated on laminin-coated dishes. The culture medium was changed to fresh medium to remove the damaged myocytes that failed to attach after 2 h in the plate. At this point, approximately 70 to 80% of myocytes were viable and rod-shaped. Gene transfer was performed by infecting cells with E1-deleted adenoviruses encoding murine AC6 (Ad.AC6) or AC6 mutant (Ad.AC6mut) at 2 × 107 virus particles per well of a 12-well plate. An adenovirus vector lacking a transgene insert (Ad.Null; Invitrogen, Carlsbad, CA) was used as an additional control.
AC Activity.
Adult rat cardiac myocytes were seeded in 12-well plates at 15 × 103 cells/well. After washing and changing media, approximately 12 × 103 cells remain in the well. Cells were incubated with Ad.AC6mut or Ad.AC6 for 44 h and stimulated for 10 min with isoproterenol (10 μM; Sigma) or forskolin (10 μM; Sigma) or were not stimulated (basal). Cells were lysed in lysis buffer 1B (2.5% dodecyltrimethyammonium bromide, 0.05 M sodium acetate, pH 5.8, and 0.02% bovine serum albumin). The amount of cAMP in the supernatant was measured using the cAMP Biotrak Enzymeimmunoassay System (GE Healthcare, Waukesha, WI) according to the instructions from the provider.
Calcineurin Activity.
Calcineurin activity was assayed using a “Calcineurin cellular activity assay kit” from Enzo Life Sciences AG (Lausen, Switzerland). In brief, cells were lysed in lysis buffer containing protease inhibitors, passed through an 18-gauge needle, and centrifuged at 16,000g at 4°C for 60 min. Supernatant was desalted by gel filtration. After the protein concentration was determined, the same amount of protein (1.1 μg) was used in calcineurin activity assay. The results (i.e., the amount of phosphate released by calcineurin) were calculated using slope and intercept obtained from standard curve.
Detection of mRNA and Protein.
Immunoblotting, immunoprecipitation, and immunofluorescence staining were performed as described previously (Gao et al., 2004, 2008).
Cardiac Myocyte Hypertrophy and Apoptosis.
To determine how AC6 and AC6mut influence cardiac myocyte response to a hypertrophic stimulus, isolated adult cardiac myocytes were infected with Ad.AC6, Ad.AC6mut, or Ad.Null for 24 h followed by incubation with phenylephrine (PE; 20 μM; Sigma) for 44 h. In alternative experiments, PE was incubated with cardiac myocytes for 24 h followed by incubation with Ad.AC6, Ad.AC6mut, or Ad.Null for 24 h. Cardiac myocyte size was measured from imaged photos using MetaMorph software (Molecular Devices, Sunnyvale, CA), an integrated morphometry analysis, stipulating a cell length of ≥107 μm. Dead cardiac myocytes, defined as small, dense, and rounded cells (Merkus et al., 2005) were counted, confirmed by exclusion of trypan blue (Zaugg et al., 2002), and expressed as a percentage of total cells. Cardiac myocyte apoptosis was determined using terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL). Total cells (untreated, 700–800; PE-treated, 500–600) and apoptotic cells were counted and expressed as a percentage of total cells. The expression of fetal genes was determined with the use of quantitative reverse transcription-polymerase chain reaction (qRT-PCR).
Measurements of Cytoplasmic Ca2+.
Cardiac myocytes were isolated from adult rat and plated on laminin-coated 25-mm glass coverslips. Cells were infected with Ad.Null, Ad.AC6, or Ad.AC6mut for 48 h and stimulated with isoproterenol (10 μM) for 20 h. Cytoplasmic Ca2+ was measured as described previously (Tang et al., 2008).
Statistical Analysis.
Data represent mean ± S.D.; group differences were tested for statistical significance using one-way ANOVA, followed by Bonferroni t testing. The null hypothesis was rejected when p < 0.05.
Results
Expression and Location of AC6mut
Both transgene AC6 and AC6mut proteins were increased 20- to 25-fold over endogenous AC6 in uninfected and Ad.Null controls (Fig. 1A) and showed distribution similar to that of plasma membrane/caveolae and sarcoplasmic reticulum (Fig. 1B).
AC6 and AC6mut Activity
Neither AC6 nor AC6mut expression altered basal cAMP (AC6, 3 ± 3 fmol/μg; AC6mut, 3 ± 2 fmol/μg; control, 2 ± 1 fmol/μg.) AC6 gene transfer was associated with increased cAMP production when stimulated with isoproterenol (AC6, 623 ± 223 fmol/μg; control, 22 ± 6 fmol/μg; p < 0.001) and forskolin (AC6, 2842 ± 133 fmol/μg; control, 636 ± 25 fmol/μg; p < 0.001) (Fig. 1C and Table 1). However, AC6mut expression was associated with a 59% reduction in cAMP production stimulated by isoproterenol (AC6mut, 9 ± 8 fmol/μg; control, 22 ± 6 fmol/μg; p > 0.05) and with an 80% reduction in forskolin stimulated cAMP production (AC6mut, 130 ± 5 fmol/μg; control, 636 ± 25 fmol/μg; p < 0.001; Fig. 1C and Table 1). These data demonstrate that AC6mut expression markedly reduces cAMP generating capacity and may interfere with endogenous AC activity.
Cardiac Myocyte Death, Apoptosis, and Hypertrophy
Cell Death.
Cultured adult cardiac myocytes contain 10% dead cells (morphological evaluation plus trypan blue confirmation) 3 days after plating. Gene transfer of AC6 and AC6mut did not change cell death rate (Fig. 2A), but PE increased cardiac myocyte death by 4.7-fold (control, 10 ± 2%; control + PE, 47 ± 2%; p < 0.001). AC6 and AC6mut gene transfer reduced PE-induced myocyte death (AC6 + PE, 20 ± 1%; AC6mut, 21 ± 3%; control + PE, 47 ± 2.0%; p < 0.001; Fig. 2A).
Apoptosis.
PE stimulation increased cardiac myocyte apoptosis (detected by TUNEL) 5.8 ± 1.2-fold over untreated controls (both uninfected and Ad.Null-infected; p < 0.001). AC6 and AC6mut gene transfer was associated with a >60% reduction in PE-induced myocyte apoptosis compared with Ad.Null-infected cells (p < 0.001; Fig. 2B). These data indicate that AC6-related attenuation of cardiac myocyte hypertrophy and apoptosis does not require cAMP generation.
Hypertrophy.
PE (20 μM for 44 h) increased cardiac myocyte area by 2.4-fold (Ad.Null + PE, 8955 ± 2940 μm2; Ad.Null (alone), 3740 ± 887 μm2; p < 0.001) without changing cell length. Gene transfer of AC6 or AC6mut did not influence cardiac myocyte area (Ad.AC6, 3643 ± 962 μm2; Ad.AC6mut, 3696 ± 990 μm2; Ad.Null, 3740 ± 887 μm2). However, both Ad.AC6 and Ad.AC6mut attenuated PE-induced cardiac myocyte hypertrophy by 36 and 31%, respectively (Ad.AC6 + PE, 5762 ± 1400 μm2; Ad.AC6mut + PE, 6153 ± 1655 μm2; control + PE: 8955 ± 2940 μm2; p < 0.01; Fig. 2C and Table 1).
In uninfected or Ad.Null-infected cells, PE increased atrial natriuretic factor (ANF) mRNA expression by 1.5-fold (p > 0.05). Increased AC6 reduced ANF expression after PE treatment, but not significantly. AC6mut acted similarly to Ad.Null control (Fig. 3A). PE increased B-type natriuretic peptide (BNP) mRNA by 2-fold (p < 0.001). Increased AC6 and AC6mut expression did not alter PE-induced BNP expression compared with Ad.Null-infected and uninfected cardiac myocytes (Fig. 3B).
CARP Expression
Next, we examined the effects of AC6 and AC6mut expression on cardiac ankyrin repeat protein (CARP), a fetal gene activated during cardiac myocyte hypertrophy (Aihara et al., 2000; Maeda et al., 2002). Ad.Null, Ad.AC6, or Ad.AC6mut gene transfer did not alter CARP expression. After PE treatment, CARP mRNA was increased in uninfected cells, unchanged in Ad.Null-infected cells, but markedly reduced in Ad.AC6- and Ad.AC6mut-infected cells. CARP protein expression was also reduced by increased AC6 and AC6mut expression (Fig. 3, C and D and Table 1). Clearly increased AC6 and AC6mut expression reduce PE-induced CARP expression, through unknown mechanisms.
Calcineurin Expression and Activity
Increased expression of calcineurin A has been described in the setting of cardiac myocyte hypertrophy (De Windt et al., 2000; Bousette et al., 2010). However, we found that PE changed neither calcineurin A expression nor calcineurin activity in all groups (Fig. 3, E and F). These data suggest that AC6 and AC6mut induced reduction in cardiac myocyte hypertrophy but not through suppression of calcineurin signaling pathway.
SR Ca2+ Storage
To determine whether AC6 or AC6mut expression was associated with alterations in SR [Ca2+], cardiac myocytes were analyzed by real-time [Ca2+]cyt imaging. No group differences in caffeine-stimulated Ca2+ transients were present (Fig. 4A). However, when stimulated with isoproterenol (1 μM, 24 h), caffeine-stimulated Ca2+ transients were increased by 2.4-fold in Ad.AC6-infected cardiac myocytes (P < 0.001; Fig. 4B and Table 1) and by 1.7-fold in Ad.AC6mut-infected cardiac myocytes (p < 0.01; Fig. 4B). An apparent difference between AC6 and AC6mut did not reach statistical significance. These data indicate that despite impaired cAMP generation, AC6mut has the ability to increase cardiac myocyte SR Ca2+ storage.
Expression and Phosphorylation of Phospholamban.
To determine possible mechanisms for the increased Ca2+ handling seen after AC6 and AC6mut gene transfer, we examined the effects of AC6 and AC6mut expression on phospholamban (PLB) and troponin I (TnI) expression and phosphorylation. Gene transfer of AC6 or AC6mut reduced PLB expression by 46 ± 18% (p < 0.05) and 41 ± 23% (p < 0.05), respectively (Fig. 5A and Table 1). The extent of PLB phosphorylation at the Ser16 or Thr17 sites in adult rat cardiac myocytes is low. Gene transfer of AC6, but not AC6mut, increased basal PLB phosphorylation at Ser16 by 7.3-fold (p < 0.001; Fig. 5B and Table 1). After isoproterenol stimulation, phospho-Ser16 was increased, but there were no group differences (Fig. 5B). AC6 and AC6mut gene transfer did not increase basal PLB phosphorylation at the Thr17 site. After isoproterenol stimulation, AC6, but not AC6mut, increased PLB phosphorylation at the Thr17 site by 2-fold (Fig. 5C and Table 1).
Cardiac Troponin-I Expression and Phosphorylation.
AC6 or AC6mut expression was not associated with alterations in cTnI expression or basal phosphorylation at p23/24 protein kinase A phosphorylation sites. After isoproterenol stimulation, phosphorylation of TnI phosphorylation was increased by expression of AC6 (1.6-fold, p < 0.001) and AC6mut (1.4-fold, p < 0.001; Fig. 5D and Table 1).
Discussion
In this study we have shown that a single amino acid substitution in the catalytic domain (C1) of AC6 resulted in marked reduction of catalytic activity. We used this catalytically inactive mutant to determine whether the benefits of AC6 gene expression are cAMP-dependent. The most important findings are that both AC6 and AC6mut attenuated PE-induced cardiac myocyte hypertrophy and cell death, reduced CARP and PLB expression, and increased Ca2+ handling. The striking similarity in the direction and degree of these changes between a catalytically active (AC6) and a catalytically inactive mutant (AC6mut) indicates that such alterations do not require increased cAMP. We conclude that many of the beneficial biological effects of AC6 do not require increases in cAMP.
We previously have shown that increased expression of AC6 in neonatal rat cardiac myocytes alters intracellular signaling events (Gao et al., 2004, 2008, 2010), but the precise mechanism has remained elusive. In the present study, we confirmed that most of the effects of AC6 expression seen in neonatal rat cardiac myocytes (Gao et al., 2004, 2008, 2009, 2010) also are present in adult rat cardiac myocytes. More importantly, in the present study, exploiting a catalytically inactive AC6 enabled us to identify the effects of AC6 expression that might be cAMP-independent. This strategy was productive and provided novel information.
cAMP-Dependent Effects.
It is important to point out that, as anticipated, not all of the effects of AC6 were cAMP-independent. For example, 1) after AC6 gene transfer, PE stimulation was associated with increased PLB phosphorylation at the Ser16 and Thr17 sites (Fig. 3, A and B), a cAMP-dependent process that did not occur after AC6mut expression; 2) expression of AC6, but not AC6mut, increased isoproterenol-induced phosphorylation of PLB at Thr17, indicating CamKII activation; and 3) AC6 and AC6mut expression did not prevent isoproterenol-stimulated increases in protein kinase A-mediated signaling (PLB phosphorylation at Ser16 or TnI phosphorylation at p23/24) or CamKII-mediated signaling (PLB phosphorylation at Thr17), indicating that activation of other endogenous ACs is not inhibited by AC6mut.
cAMP-Independent Effects.
How do AC6 and AC6mut influence intracellular signaling independently of increases in cAMP generation? Based on our previous studies of AC6 expression in neonatal cardiac myocytes, we speculate that increased expression of AC6 and AC6mut enable interactions with intracellular proteins that previously were inaccessible. For example, coimmunoprecipitation and immunohistology indicate close associations of intracellular AC6 with a specific phosphatase (Brognard et al., 2007; Gao et al., 2009). Others have found that the N terminus of AC6 interacts with snapin protein, linking AC6 to snapin-binding protein complexes (Wang et al., 2009), which may enable AC6 and AC6mut to function independently of cAMP. We recently discovered that increased AC6 and AC6mut expression are associated with α-B-crystallin (data not shown), although the biological consequence of this interaction is presently unknown. It is also plausible that AC6 and AC6mut are interfering with normal signaling by preferentially associating with key intracellular signaling proteins such as G protein-coupled receptors, Gαs, Gβγ, and scaffold proteins such as A-kinase anchoring proteins, thus serving a dominant-negative function, which could also influence the hypertrophic response. For example, we found that AC6mut inhibited forskolin-stimulated AC activity (Fig. 1C). Although forskolin is a direct AC activator, its effectiveness is influenced by the presence of Gαs. In cells lacking Gαs, forskolin-stimulated cAMP production was reduced (Darfler et al., 1982). Our data suggest that AC6mut acts as a dominant-negative mutant by interacting with Gαs to reduce the effects of Gαs on endogenous AC responsiveness to forskolin. Identification of AC6-interacting proteins and the consequences of such interactions in adult cardiac myocytes is a focus of study in our laboratories.
Inhibition of Hypertrophy.
PE, an α1-adrenergic receptor agonist, induces cardiac myocyte hypertrophy (Simpson, 1985) and cell death. Many genes are involved in PE-induced cardiac myocyte hypertrophy. For example, transcription of CARP is increased in PE-induced hypertrophy (Pinson et al., 1993). In the present study, expression of AC6 or AC6mut reduced CARP expression and attenuated hypertrophy through unknown mechanisms. Increased expression of AC6 in vivo was not associated with altered expression of βAR, Gαs, or Giα2 (Gao et al., 1999), so the attenuation of hypertrophy observed after expression of AC6 or AC6mut in the present study is not likely to be mediated through the β-adrenergic receptor-signaling pathway. Moreover, AC6mut and AC6, which have opposite effects on cAMP production, have similar effects on the attenuation of hypertrophy.
Adult rat cardiac myocyte hypertrophy was confirmed by measuring protein synthesis using [3H]leucine incorporation. As expected, when uninfected and Ad.Null-infected cardiac myocytes were treated with phenylephrine, we saw increased apoptosis and necrosis. Protein synthesis was decreased by 20% compared with cardiac myocytes not treated with phenylephrine. In essence, the confounding elements of increases in apoptosis and cell death make protein synthesis measurements less desirable than evaluating hypertrophy based on size of viable cells in this model. Nevertheless, in PE-treated groups, AC6 and AC6mut gene transfer decreased cell size and reduced protein synthesis by 25 and 16% respectively.
AC6 (but not AC6mut) expression increased PLB phosphorylation at Ser16 and Thr17 in response to PE stimulation (Fig. 3, A and B). These data suggest that protein kinase A and CamKII are not involved in attenuation of PE-induced hypertrophy. Expression of AC6 or AC6mut did not alter the expression of hypertrophy-associated genes such as ANF and BNP, did not increase calcineurin A expression, and did not influence the extracellular signal-regulated kinase signaling pathway (data not shown), but inhibited CARP expression (Fig. 3, C and D), which is likely to contribute to the attenuation of hypertrophy.
We recently reported that AC6 deletion reduced left ventricular hypertrophy in pressure-overloaded female mice (Tang et al., 2010), which seems counter to what we found regarding cardiac myocyte hypertrophy in the present study. However, because of the influence of targeted expression and deletion of specific genes on nontargeted proteins, it is not axiomatic that increased expression of AC6 should result in directionally opposite effects versus AC6 deletion. A simple example illustrates this point. In the AC6 targeted deletion lines, we saw a marked diminution in cardiac AC5 protein levels. AC5 mRNA expression was unchanged, but the deletion of AC6 was associated with marked increases in AC5 protein degradation (Tang et al., 2008). AC5 deletion is associated with reduced LV hypertrophy in pressure overload (Yan et al., 2007)—its absence in AC6-deleted lines may explain reduced hypertrophy in pressure overload (Tang et al., 2010). Second, by increasing the expression of AC6 (or AC6mut), the likelihood of interactions with intracellular proteins (not usually accessible to endogenous levels of AC6) is increased—a condition not present in the setting of AC6 deletion. Furthermore, the responses of cardiac myocytes in vitro to short-term changes in milieu are often not replicated by cardiac myocytes in vivo, which naturally reflect more long-term responses to alterations in physiological conditions. Finally, regarding the physiological correlates of the findings of the current studies in relation to hypertrophic responses in vivo, we see improved LV function after pressure overload hypertrophy in mice with cardiac-directed expression of AC6 (N. C. Lai and H. K. Hammond, unpublished data), although LV hypertrophy is similar to that observed in transgene negative siblings.
Ca2+ Handling.
AC6 expression (but not AC6mut expression) was associated with isoproterenol-induced PLB phosphorylation at Thr17. Expression of AC6 and AC6mut was associated with reduced PLB expression and increased cytoplasmic Ca2+ concentration in response to caffeine stimulation (Fig. 4). Although AC6mut expression did not increase isoproterenol-stimulated PLB phosphorylation at Thr17, its beneficial effects on Ca2+ handling are likely to reflect reduced PLB expression, which was also seen after AC6 expression. Previous studies have established the tight linkage between levels of AC6 and calcium handling in the heart. For example cardiac-directed expression of AC6 was associated with increased SR Ca2+ uptake (Tang et al., 2004). In contrast, hearts from AC6-deleted mice show substantially impaired Ca2+ handling (Tang et al., 2008).
Conclusions
Expression of a catalytically inactive mutant of AC6 exhibited many of the beneficial biological effects seen with expression of the catalytically active normal AC6. Both AC6 and AC6mut reduced PLB expression, increased Ca2+ handling, and reduced PE-induced cardiac myocyte hypertrophy and cell death. These data indicate that the favorable effects associated with cardiac AC6 expression are not solely dependent upon increases in cAMP generation.
Authorship Contributions
Participated in research design: Gao, T. Tang, Lai, Yuan, and Hammond.
Conducted experiments: Gao, R. Y. Tang, Guo, and Firth.
Contributed new reagents or analytic tools: Miyanohara.
Performed data analysis: Gao.
Wrote or contributed to the writing of the manuscript: Gao and Hammond
Other: Gao and Hammond acquired funding for the research.
Acknowledgments
We are grateful to Drs. James Feramisco and Kersi Pestonjamasp for imaging and Diana Huang for isolation of adult rat cardiac myocytes.
Footnotes
This work was supported by the National Institutes of Health National Heart, Lung, and Blood Institute [Grants 5P01-HL066941, HL081741, HL088426-01]; a Department of Veterans Affairs merit grant; and American Heart Association Beginning Grant-In-Aid Awards [0765064Y, 0865147F].
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
doi:10.1124/mol.110.067298.
-
ABBREVIATIONS:
- AC
- adenylyl cyclase
- AC6
- adenylyl cyclase type 6
- AC6mut
- adenylyl cyclase type 6 mutant
- PHLPP2
- pleckstrin homology domain leucine-rich repeat protein phosphatase 2
- Ad.AC6
- E1-deleted adenoviruses encoding murine AC6
- Ad.AC6mut
- E1-deleted adenoviruses encoding murine AC6 mutant
- PE
- phenylephrine
- TUNEL
- terminal deoxynucleotidyl transferase dUTP nick-end labeling
- qRT-PCR
- quantitative reverse transcription-polymerase chain reaction
- BNP
- B-type natriuretic peptide
- CARP
- cardiac ankyrin repeat protein
- PLB
- phospholamban
- TnI
- troponin I
- cTnI
- cardiac troponin-I
- CamKII
- calcium/calmodulin-dependent protein kinase II
- ANF
- atrial natriuretic factor
- LV
- left ventricular
- SR
- sarcoplasmic reticulum
- ANOVA
- analysis of variance.
- Received July 1, 2010.
- Accepted December 1, 2010.
- U.S. Government work not protected by U.S. copyright